1. e-Poster
159
VEPTR Implantation to Treat Children with Early Onset Scoliosis without Rib Abnormalities: A Prospective Multicenter Study
Ron El-Hawary, Muayad Kadhim, Michael Vitale, John Smith,
Amer Samdani, Jack Flynn, Children's Spine Study Group
Level of Evidence: II
Please refer to ICEOS program for authors’ disclosures.

2. PRIMARY OBJECTIVE
Study design: Prospective, Non-randomized, Multicenter clinical study.
Inclusion criteria:
Progressive early onset scoliosis (EOS) in children without rib abnormality (18 months to 10 years of age with open triradiate cartilages).
Scoliosis that has advanced beyond 45˚
Study hypothesis:
VEPTR is effective to prevent further progression of EOS and allows for, or at least, does not prevent spinal growth.

3. Results n= 63 patients: Males: 35 (56%) Females: 28 (44%)
Mean age at surgery = 6.1 ± 2.4 years.
Mean Follow up = 2.2 ± 0.4 years.
Etiology:
Congenital: 6, (10%)
Neuromuscular: 36, (57%)
Syndromic: 4, (6%)
Idiopathic: 17, (27%)
Scoliosis severity:
20-50 = 7 (11%)
50-90 = 52 (83%)
>90 = 4 (6%)
Kyphosis severity
<20 = 4 (6%)
20 – 50 = 29 (48%)
>50 = 28 (46%)

7. Results Prevent EOS progression: 86% T1-T12 Height
Progressive EOS without rib abnormalities +
VEPTR device
Successful treatment
Prevent EOS progression: 86%
Allow T1-S1 growth: 94%
Prevent EOS and allow spine growth: 79%
Successfully allows spine growth
T1-T12 Height
(144% of expected age-matched T1-T12 growth)
T1-S1 Height
(193% of expected age-matched T1-S1 growth)

8. Conclusion
VEPTR was effective in treating EOS without rib abnormalities at 2 years follow-up.
86% of patients had an improvement in EOS and 94% of patients had an increased spinal height as compared to pre-operative values.
Coronal spine height increased by 144% of expected age-matched T1-T12 growth and by 193% of expected age-matched T1-S1 growth.